Craig A Bollig1, Christopher I Newberry2, Tabitha L I Galloway3, Robert P Zitsch3, Elyse K Hanly4, Vivian L Zhu4, Nitin Pagedar4, Rohit Nallani5, Andres M Bur5, William C Spanos6, Jeffrey B Jorgensen7. 1. Department of Otolaryngology-Head and Neck Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, U.S.A. 2. Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of Utah School of Medicine, Salt Lake City, Utah, U.S.A. 3. Department of Otolaryngology-Head and Neck Surgery, University of Missouri School of Medicine, Columbia, Missouri, U.S.A. 4. Department of Otolaryngology-Head and Neck Surgery, University of Iowa School of Medicine, Iowa City, Iowa, U.S.A. 5. Department of Otolaryngology-Head and Neck Surgery, University of Kansas School of Medicine, Kansas City, Kansas, U.S.A. 6. Sanford Cancer Center, Sanford Health, Sioux Falls, South Dakota, U.S.A. 7. Department of Otolaryngology-Head and Neck Surgery and Communication Disorders, University of Louisville School of Medicine, Louisville, Kentucky, U.S.A.
Abstract
OBJECTIVES/HYPOTHESIS: Investigate the relationship between site and pattern of distant metastasis (DM) and overall survival (OS) in a multi-institutional cohort of patients with DM head and neck cancer (HNC). STUDY DESIGN: Retrospective review. METHODS: 283 patients treated at 4 academic centers in the Midwest HNC Consortium between 2000 and 2015 were retrospectively reviewed. Disease patterns were divided between solitary metastatic versus polymetastatic (≥2 sites) disease. Survival functions for clinically relevant variables were estimated using Kaplan-Meier and Cox proportional hazards models. RESULTS: Median OS for all patients was 9.0 months (95% confidence interval [CI]: 7.4-10.6). Lung (n = 220, 77.7%) was the most common site of DM, followed by bone (n = 90, 31.8%), mediastinal lymph nodes (n = 55, 19.4%), liver (n = 41, 14.5%), and brain (n = 17, 6.0%). Bone metastases were independently associated with the worst prognosis (hazard ratio [HR] = 1.6, 95% CI: 1.3-2.1). On univariate analysis, brain metastases were associated with improved prognosis (HR = 0.5, 95% CI: 0.3-0.9), although this was not statistically significant on the multivariate analysis. Polymetastatic disease was present in the majority of patients (n = 230, 81.3%) and was associated with a worse prognosis compared to solitary metastatic disease (HR = 1.4, 95% CI: 1.0-2.0). CONCLUSION: Our large, multi-institutional review indicates that both the metastatic pattern and site of DM impact OS. Polymetastatic disease and bone metastasis are associated with worse prognosis, independent of treatment received. LEVEL OF EVIDENCE: 4 Laryngoscope, 131:E1838-E1846, 2021.
OBJECTIVES/HYPOTHESIS: Investigate the relationship between site and pattern of distant metastasis (DM) and overall survival (OS) in a multi-institutional cohort of patients with DM head and neck cancer (HNC). STUDY DESIGN: Retrospective review. METHODS: 283 patients treated at 4 academic centers in the Midwest HNC Consortium between 2000 and 2015 were retrospectively reviewed. Disease patterns were divided between solitary metastatic versus polymetastatic (≥2 sites) disease. Survival functions for clinically relevant variables were estimated using Kaplan-Meier and Cox proportional hazards models. RESULTS: Median OS for all patients was 9.0 months (95% confidence interval [CI]: 7.4-10.6). Lung (n = 220, 77.7%) was the most common site of DM, followed by bone (n = 90, 31.8%), mediastinal lymph nodes (n = 55, 19.4%), liver (n = 41, 14.5%), and brain (n = 17, 6.0%). Bone metastases were independently associated with the worst prognosis (hazard ratio [HR] = 1.6, 95% CI: 1.3-2.1). On univariate analysis, brain metastases were associated with improved prognosis (HR = 0.5, 95% CI: 0.3-0.9), although this was not statistically significant on the multivariate analysis. Polymetastatic disease was present in the majority of patients (n = 230, 81.3%) and was associated with a worse prognosis compared to solitary metastatic disease (HR = 1.4, 95% CI: 1.0-2.0). CONCLUSION: Our large, multi-institutional review indicates that both the metastatic pattern and site of DM impact OS. Polymetastatic disease and bone metastasis are associated with worse prognosis, independent of treatment received. LEVEL OF EVIDENCE: 4 Laryngoscope, 131:E1838-E1846, 2021.
Authors: Thomas F Barrett; Corey M Gill; Brett A Miles; Alfred M C Iloreta; Richard L Bakst; Mary Fowkes; Priscilla K Brastianos; Joshua B Bederson; Raj K Shrivastava Journal: Neurosurg Focus Date: 2018-06 Impact factor: 4.047
Authors: Robert P Takes; Alessandra Rinaldo; Carl E Silver; Missak Haigentz; Julia A Woolgar; Asterios Triantafyllou; Vanni Mondin; Daniela Paccagnella; Remco de Bree; Ashok R Shaha; Dana M Hartl; Alfio Ferlito Journal: Oral Oncol Date: 2012-04-18 Impact factor: 5.337
Authors: James J Jaber; Lauren Murrill; Joseph I Clark; Jonas T Johnson; Paul J Feustel; Vikas Mehta Journal: Otolaryngol Head Neck Surg Date: 2015-04-27 Impact factor: 3.497
Authors: Thomas H Beckham; Jonathan E Leeman; Peng Xie; Xiaolin Li; Debra A Goldman; Zhigang Zhang; Eric Sherman; Sean McBride; Nadeem Riaz; Nancy Lee; C Jillian Tsai Journal: Br J Cancer Date: 2019-10-25 Impact factor: 7.640